6th Annual MarketsandMarkets

Neuroscience R&D Conference

9th - 10th October 2023

Ibis London Earls Court Hotel & ILEC Conference Centre

Unfolding the recent advancements in preclinical and translational approaches treating neurodegenerative disorders.

With the advent of neural implants and novel therapies, the cure of multiple neurodegenerative disorders proves wholesome for the patients’ suffering. Increasing in the severity of neurodegenerative diseases, demands the discovery of new translational approaches in neuroscience research.

Tag Line
Learn from 20+ industry leading speakers who will be sharing their presentations on CNS drug discovery, Latest Optogenetic tools, kinematic techniques, Blood-Brain Barrier Proteomics and Non-Invasive electrical brain stimulation.
Tag Line
Case studies presented from leading technology collaborations, Interactive panel and breakout sessions along with Access to online presentations on-demand post-summit.
Tag Line
First ever conference on application of technology in developing neurological treatments. Meet 100+ global heads of neuroscience from the industry and Academics.

MarketsandMarkets 6th Annual Neuroscience R&D conference to be held on 9th - 10th October 2023 at Ibis London Earls Court Hotel & ILEC Conference Centre aims to offer a wide space to the experts from academia and industry together to discuss novel therapeutics, emerging trends, major challenges, and interesting revolutions that could be blooming in neuroscience in near future. The conference will be centred on focusing on the most recent advancements in preclinical, translational neuroscience research while also bringing the audience's attention to the emerging role of AI and big data in neuroscience R&D space. This two-day programme will feature expert keynote presentations, cutting-edge discussions, and live case studies, giving stakeholders the chance to participate in this scientific meeting and network with industry peers while staying up to date on the most recent advancements in neuroscience research.

WHAT TO EXPECT

  • Human iPSCs-derived Models in Neuroscience Researce
  • Neurodegeneration and Novel Translational Approaches
  • Therapeutic Antibodies for Neurodegenerative disorders
  • Disease Modelling and Drug Discovery
  • Role of Genetics and epigenetics in Neurodegeneration
  • Inclusion of AI and digital biomarkers in neuropathology
  • Emerging optogenetics tools: Studying Synaptic Plasticity
  • Neural Implants to treat Neurological Conditions
  • Neuromodulation and Brain Stimulation Techniques 

  • To share and exchange the recent trends and technologies in neuroscience R&D.
  • Participate in discussions with experts on how technology implementation can be improved.
  • To better understand neurological factors that will help in drug designing.
  • Discover how AI and big data advancements is boosting neuroscience developments.
  • Discover the various issues and challenges coming up in neuroscience research.
  • Gain Knowledge on the progress of neurodegenerative disorders and their possible treatments.
  • Opportunity for networking with professionals, delegates, and speakers.

Designations:

  • CEO
  • CSO
  • CMO
  • COO
  • President
  • Vice President
  • Director 
  • Head of Department
  • Executive leader
  • Senior Manager
  • Manager
  • Principle Scientist
  • Scientist
  • Neuroscientist
  • Professor
  • Associate Professor
  • Lecturer
  • Researcher

Working in the department:

  • Neuroscience/CNS drug discovery
  • Pre-clinical research
  • Neurobiology
  • Neurotechnology
  • Neuroinflammation
  • Neuroimmunology
  • Neurodegenerative diseases
  • Translational Neuroscience
  • Neuropharmacology
  • Neuroimaging /Translational Imaging
  • AI and Big data in neuroscience
  • Computational Neuroscience
  • Neural Engineering
  • Neurophysiology

CONFERENCE AGENDA

Registration

08:40 - 09:20

Welcome note from MarketsandMarkets

09:20 - 09:25

Opening Remarks from the Chairperson

Michela Chiappalone

Michela Chiappalone , Associate Professor, University of Genova

09:25 - 09:30

Keynote Presentation: Neuroprotective therapeutics: from monomodal to multimodal strategies

Alan Palmer

Alan Palmer, Chief Executive Officer, Elixa MediScience, UK

09:30 - 10:00

CRACKING THE CODE OF NEURODEGENERATION: GROUNDBREAKING APPROACHES TO UNPRECEDENTED THERAPIES

Systemic inflammation induced by lipopolysaccharide modulates Alzheimer’s disease progression

Marie Christine Pardon

Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham

10:00 - 10:30

Parkinson’s disease : alpha-synuclein toxicity and spreading, in vitro and in vivo models.

Dr. Noelle Callizot

Dr. Noelle Callizot, Chief Scientific Officer, Neuro-Sys

10:30 - 11:00

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

11:00 - 11:40

Patient-Led Discovery of Disease-Relevant Antibodies and Targets

Paulina Kolasinska-Zwierz

Paulina Kolasinska-Zwierz, Principal Scientist, Alchemab Therapeutics

11:40 - 12:10

Alzheimer’s Diseases: Translational Models and Brain-on-Chip innovations

Dr. Jerome Bernard

Dr. Jerome Bernard, Chief Business Officer, ETAP-Lab

12:10 - 12:40

TRP channels in glia: therapeutic potential?

Mark Dallus

Mark Dallus, Professor in cellular neuroscience, University of Reading

12:40 - 13:10

Functional Phenotypic Models for Amyotrophic Lateral Sclerosis with human iPSC Motor derived Neurons

Olaf Schroder

Olaf Schroder, CEO, Neuroproof, Germany

13:10 - 13:40

Lunch and Poster Presentation | One-to-One Networking Meetings

13:40 - 14:40

MODELLING NEUROLOGICAL DISEASES USING IPSC-DERIVED NEURAL CELLS

Use of human stem cell models of neurological disease to advance drug discovery

Clare Jones

Clare Jones, Chief Scientific Officer, Talisman therapeutics

14:40 - 15:10

Enabling precision medicine using human iPSC models and clinical research

Zameel Cader

Zameel Cader, Professor of Neuroscience and Neurology, University of Oxford

15:10 - 15:40

Cutting-edge iPSC platform at UCB for neurology indications

Martine Geraerts

Martine Geraerts, Director Cell biology, In-vitro Pharmacology, UCB Pharma

15:40 - 16:10

Evening Refreshments and Poster Presentation | One-to-One Networking Meetings

16:10 - 16:50

Human neuronal networks on micro-electrode arrays are a robust tool to study disease phenotype in vitro

Monica Frega

Monica Frega, Assistant Professor, University of Twente

16:50 - 17:20

Panel Discussion: Experimental models in vitro: barriers and challenges to reproduce the complexity of the brain.

Marie Christine Pardon

Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham

Clare Jones

Clare Jones, Chief Scientific Officer, Talisman therapeutics

Zameel Cader

Zameel Cader, Professor of Neuroscience and Neurology, University of Oxford

Monica Frega

Monica Frega, Assistant Professor, University of Twente

Alan Palmer

Alan Palmer, Chief Executive Officer, Elixa MediScience, UK

17:20 - 17:50

Closing Remarks from the Chairperson

17:50 - 18:00

Drinks Reception & Networking

18:00 - 18:00

End of Day 1

18:00 - 18:00

Registration

08:10 - 08:45

Welcome note from MarketsandMarkets

08:45 - 08:50

Opening Remarks from the Chairperson

Patrick Degenaar

Patrick Degenaar, Professor in Neuroprosthetics, Newcastle University

Marie Christine Pardon

Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham

08:50 - 08:55

Keynote Presentation: Improving everyday life through Applied Neuroscience

Naomi Glover

Naomi Glover, Co-Founder / Director, Applied Neuroscience Association

08:55 - 09:25

INLCUSION OF AI, DIGITAL BIOMARKERS WITH CNS MODELS & NEUROMODULATION TECHNIQUES

iPSC-microglia and other glial cells

Jennifer Pocock

Jennifer Pocock, Professor, University College London

09:25 - 09:55

The challenge of privacy in AI models: Assessing the risk of Artificial Intelligence (AI), which uses multi-modal healthcare data, and how we can preserve privacy within them.

Lewis Hotchkiss

Lewis Hotchkiss, Data Scientist, Neuroimaging Researcher, Dementia Platform UK

09:55 - 10:25

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:25 - 11:10

Translational challenges in developing a novel target for psychiatric disorders

Clíona MacSweeney

Clíona MacSweeney, Neuroscience Program Leader, Sosei Heptares

11:10 - 11:40

Digital Biomarker Strategies for Successful Development of Neuroscience Targets

Kiri Granger

Kiri Granger, Chief Scientific Officer, Monument Therapeutics

11:40 - 12:10

Neuroengineering: the novel frontier for restoring neural functions

Michela Chiappalone

Michela Chiappalone , Associate Professor, University of Genova

12:10 - 12:40

The future of neural implants to treat neurological conditions

Patrick Degenaar

Patrick Degenaar, Professor in Neuroprosthetics, Newcastle University

12:40 - 13:10

Lunch and Poster Presentation | One-to-One Networking Meetings

13:10 - 14:10

tVNS research in neurorehabilitation.

Dr. Ali Ali

Dr. Ali Ali, Senior Clinical Lecturer Cerebrovascular Disease, University of Sheffield

14:10 - 14:40

Panel Discussion: Ethical Dilemmas Surrounding Neuromodulation and Brain-Computer Interfaces (BCIs): A Deliberation on Principles and Practices

Patrick Degenaar

Patrick Degenaar, Professor in Neuroprosthetics, Newcastle University

Michela Chiappalone

Michela Chiappalone , Associate Professor, University of Genova

Lewis Hotchkiss

Lewis Hotchkiss, Data Scientist, Neuroimaging Researcher, Dementia Platform UK

Dr. Ali Ali

Dr. Ali Ali, Senior Clinical Lecturer Cerebrovascular Disease, University of Sheffield

14:40 - 15:10

Closing Remarks from the Chairperson

Patrick Degenaar

Patrick Degenaar, Professor in Neuroprosthetics, Newcastle University

15:10 - 15:10

End of the conference

15:10 - 15:10

SPEAKERS

Alan Palmer

Alan Palmer

Chief Executive Officer, Elixa MediScience, UK

Olaf Schroder

Olaf Schroder

CEO, Neuroproof, Germany

Dr. Ali Ali

Dr. Ali Ali

Senior Clinical Lecturer Cerebrovascular Disease, University of Sheffield

Paulina Kolasinska-Zwierz

Paulina Kolasinska-Zwierz

Principal Scientist, Alchemab Therapeutics

Clíona MacSweeney

Clíona MacSweeney

Neuroscience Program Leader, Sosei Heptares

Martine Geraerts

Martine Geraerts

Director Cell biology, In-vitro Pharmacology, UCB Pharma

Dr. Jerome Bernard

Dr. Jerome Bernard

Chief Business Officer, ETAP-Lab

Jennifer Pocock

Jennifer Pocock

Professor, University College London

Dr. Noelle Callizot

Dr. Noelle Callizot

Chief Scientific Officer, Neuro-Sys

Kiri Granger

Kiri Granger

Chief Scientific Officer, Monument Therapeutics

Naomi Glover

Naomi Glover

Co-Founder / Director, Applied Neuroscience Association

Lewis Hotchkiss

Lewis Hotchkiss

Data Scientist, Neuroimaging Researcher, Dementia Platform UK

Marie Christine Pardon

Marie Christine Pardon

Assistant Professor in Translational Neuroscience, University of Nottingham

Clare Jones

Clare Jones

Chief Scientific Officer, Talisman therapeutics

Patrick Degenaar

Patrick Degenaar

Professor in Neuroprosthetics, Newcastle University

Monica Frega

Monica Frega

Assistant Professor, University of Twente

Michela Chiappalone

Michela Chiappalone

Associate Professor, University of Genova

Mark Dallus

Mark Dallus

Professor in cellular neuroscience, University of Reading

Zameel Cader

Zameel Cader

Professor of Neuroscience and Neurology, University of Oxford

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Ibis London Earls Court Hotel & ILEC Conference Centre

PAST EVENT GALLERY